-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Abigail Hirsch
Approval for AIDS Vaccine at Canadian University
The Food and Drug Administration has given Canadian researchers approval to test a vaccine for HIV/AIDS on humans. Researchers from the University of Western Ontario are hopeful that with further tests, a vaccine could be on the market in about five years. Similar to the approaches used to develop vaccines for polio, influenza, rabies and hepatitis A, the vaccine is the first based on a genetically modified, killed whole virus and is the only HIV Read More >
Opportunity or Apocalypse? Prophecies for 2012
On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >
Resistance is Futile – SuperDrugs for SuperBugs
“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >
BIO Convention rookie no longer
As the saying goes, there is nothing quite like learning on the job and no truer words could be spoken about my experience with this year’s BIO International Convention. Having joined the Communications Department less than two months prior to the largest event of the year, my start date was in the height of Convention preparation. Each day at the office was consumed by learning, retaining and contributing as much as possible to the Convention Read More >
Get Active at the 2011 BIO International Convention
According to the American College of Sports Medicine, Washington, DC tops the ranks of the fittest cities in the nation. With the 2011 BIO International Convention quickly approaching, BIO hopes visitors will get active. From the BIO 5K Run/Walk to the BIO Golf Outing (both hosted by Novo Nordisk Inc) to the various outdoor activities right at our fingertips in the nation’s capital, attendees are encouraged to get outside and take advantage of all the Read More >




